GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (GREY:PSTTF) » Definitions » Median PS Value

Prescient Therapeutics (Prescient Therapeutics) Median PS Value : $0.00 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Prescient Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Prescient Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0. Prescient Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-05), Prescient Therapeutics's share price is $0.145. Prescient Therapeutics's Median PS Value is $0.00. Therefore, Prescient Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Prescient Therapeutics's Median PS Value or its related term are showing as below:

PSTTF's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Prescient Therapeutics Median PS Value Historical Data

The historical data trend for Prescient Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Median PS Value Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prescient Therapeutics's Median PS Value

For the Biotechnology subindustry, Prescient Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Price-to-Median-PS-Value falls into.



Prescient Therapeutics Median PS Value Calculation

Prescient Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prescient Therapeutics  (GREY:PSTTF) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Prescient Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.145/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prescient Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (Prescient Therapeutics) Business Description

Traded in Other Exchanges
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.